Form D · Biotechnology
Outlook Therapeutics, Inc.
Iselin, NJ · CIK 0001649989
Offering snapshot reported May 7, 2026 · SEC filing
- Reported sold
- $0 Offering amount: $5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 23, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 7, 2026 | Initial | $0 | No comparison | 2 | SEC filing |
| Jan 27, 2025 | Initial | $0 | No comparison | 10 | SEC filing |
| Apr 16, 2024 | Initial | $5,000,002 | No comparison | 1 | SEC filing |
| Mar 29, 2024 | Initial | $60,000,000 | No comparison | 21 | SEC filing |
| Jan 6, 2023 | Initial | $31,820,000 | No comparison | 1 | SEC filing |
| Jan 6, 2023 | Initial | $1,031,510 | No comparison | 1 | SEC filing |
| Feb 12, 2021 | Initial | $4,013,627 | No comparison | 2 | SEC filing |
| Jun 9, 2020 | Initial | $16,000,000 | No comparison | 1 | SEC filing |
| Mar 11, 2020 | Initial | $7,971,155 | No comparison | 7 | SEC filing |
| Sep 25, 2017 | Initial | $3,262,800 | No comparison | 1 | SEC filing |
| Dec 23, 2015 | Initial | $6,345,960 | No comparison | 11 | SEC filing |
| Oct 13, 2015 | Initial | $14,480,486 | No comparison | 4 | SEC filing |
| Aug 10, 2015 | Initial | $31,050,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $485K
- Form D file number
- 021-583245
The total offering amount above represents the amount, if any, that the Issuer could receive if all of the issued Warrants were exercised. As of the date of this filing, none of the warrants have been exercised.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed May 7, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gerd Auffarth | Director |
| Kenneth M. Bahrt | Executive |
| Todd C. Brady | Director |
| Scott Canute | Director |
| Terry Dagnon | Executive |
| Albert D. Dyrness | Director |
| Jeff Evanson | Executive |
| Scott A. Gangloff | Executive |
| Julian Gangolli | Director |
| Donald J. Griffith | Director |
| Yezan Haddadin | Director |
| Julia A. Haller | Director |
| Kurt J. Hilzinger | Director |
| Robin Hoke | Director |
| Andong Huang | Director |
| Lawrence A. Kenyon | Director, Executive |
| Stephen J. Mc Andrew | Executive |
| Pankaj Mohan | Director, Executive |
| Faisal G. Sukhtian | Director |
| Joe Thomas | Director |
| Randy H. Thurman | Director |
| C. Russell Trenary | Director, Executive |
| Elizabeth Yamashita | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
111 S. Wood Avenue Unit #100
Iselin, NJ, 08830
Iselin, NJ, 08830